Web23 mrt. 2024 · Tominersen, previously IONIS-HTT Rx or RG6042, is an investigational antisense therapy designed to reduce the production of all forms of the huntingtin protein (HTT), including its mutated variant, mHTT. In December 2024, Roche licensed the investigational molecule from Ionis. Web9 mrt. 2024 · I've stayed silent...very silent, since the press release on March 1, 2024, from Ionis Pharmaceuticals, Inc.: "IONIS-HTT Rx (RG6042) Top-Line Data Demonstrate Significant Reductions of Disease-Causing Mutant Huntingtin Protein in People with Huntington's Disease" The Huntington's community waited patiently for this update …
Ionis
WebEHDN statement: Next steps in the development of Ionis/Roche HTTRx antisense oligonucleotide (ASO) program for Huntington’s disease. Many in the HD community are now aware of the initial IONIS-HD HTTRx clinical trial results and have questions. EHDN Central Coordination have compiled the following statement for anyone interested. Web13 apr. 2024 · Scott Schobel, MD, MSc. Tominerson (Roche), formerly known as IONIS-HTT Rx and RG6042, made history in May 2024 when results from a phase 1/2a trial published in the New England Journal of Medicine demonstrated that the investigational antisense oligonucleotide was the first therapeutic to successfully target and reduce levels of … the philippine flag was hoisted on
Ionis huntingtin-lowering trial is good news for HD Families - but …
Web2 Ionis Pharmaceuticals, Carlsbad, CA, USA. PMID: 29856033 DOI: 10.1007/978-1-4939-7825-0_23 Abstract ... Huntington's disease (HD), which is caused by a CAG repeat expansion in exon 1 of the huntingtin (HTT) gene and leads to the pathogenic expansion of a polyglutamine ... WebDear members of the Huntington’s community, Today is an exciting day for the Huntington’s disease community. The Phase 1/2a Study of IONIS-HTTRx, the first therapy in clinical development designed to target the underlying cause of HD, has been completed. We are pleased to share an update on the status of the IONIS-HTTRx program and its … Web24 dec. 2024 · Over the years, centrally administered ASOs have demonstrated widespread CNS tissue distribution, activity, and substantial phenotypic prevention and/or reversal in mouse models of Huntington's , SMA , Frontotemporal dementia , Parkinson's , TDP-43- and C9orf72-linked ALS , Alexander disease , Pelizaeus-Merzbacher disease , Prion … sick chicken treatment